Substance / Medication

Teprotumumab

Overview

Active Ingredient
teprotumumab
RxNorm CUI
2274803

Indications

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Labeler: Horizon Therapeutics USA, Inc.Updated: 2025-11-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Patterns of Teprotumumab-Induced Hearing Dysfunction: A Systematic Review.
Wong Kevin, Arya Priya, Salmeron Yansy et al. · Otolaryngol Head Neck Surg · 2025
PMID: 39194388Meta-AnalysisFull text (PMC)
Teprotumumab for treating active thyroid eye disease: A meta-analysis.
Cong Xiangguo, Pei Leilei, Hu Honglei · Medicine (Baltimore) · 2025
PMID: 40587732Meta-AnalysisFull text (PMC)
Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis.
Huang Wenxin, Ou Xiaodan, Lin Shuzhen et al. · Endocr Pract · 2025
PMID: 39952471Meta-Analysis
Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves' orbitopathy: a systematic review and meta-analysis.
Abumohssin Abdulelah G, Alshareef Rayan A, Aljohani Saja et al. · Eye (Lond) · 2025
PMID: 40404973Meta-AnalysisFull text (PMC)
Teprotumumab's Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis.
Householder Nicholas A, Ray Coby · touchREV Endocrinol · 2024
PMID: 39526058Meta-AnalysisFull text (PMC)
The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials.
Lin Fei, Yao Qiu'e, Yu Bin et al. · Int J Clin Pract · 2023
PMID: 37588100Meta-AnalysisFull text (PMC)
Teprotumumab for the treatment of thyroid eye disease.
Ju Yongjing, Yang Junyi · Expert Rev Clin Immunol · 2020
PMID: 32707005Meta-Analysis
Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas Raymond S, Couch Steven, Wester Sara T et al. · J Clin Endocrinol Metab · 2023
PMID: 37925673RCTFull text (PMC)
Improvement of asymmetric thyroid eye disease with teprotumumab.
Ugradar Shoaib, Wang Yao, Mester Tunde et al. · Br J Ophthalmol · 2022
PMID: 33579690RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Teprotumumab (substance)
SNOMED CT
840364008
UMLS CUI
C2987429
RxNorm CUI
2274803
Labeler
Horizon Therapeutics USA, Inc.

Clinical Data

This intervention maps to 0 entities in the Healos knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.